Price movement over the last 24 hours
Airbnb, Inc. vs Amphastar Pharmaceuticals Inc — how do they compare? Airbnb, Inc. trades at $142.9 (market cap $88.31B), while Amphastar Pharmaceuticals Inc trades at $18.84 (market cap $885.83M). The key difference: Airbnb, Inc. is far larger — about 99.7× Amphastar Pharmaceuticals Inc's market cap, and Airbnb, Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ABNB | AMPH | |
|---|---|---|
Market Cap | $88.31B | $885.83M |
Sector | Consumer Cyclical | Health |
52-Week High | $148.93 | $30.81 |
52-Week Low | $111.54 | $16.87 |
Enterprise Value | $78.84B | $1.28B |
Signals from Pluang's Aura AI — not financial advice
Airbnb (ABNB) trades at $148.80, showing minimal daily movement with a slight decline of 0.09%. The stock maintains a bullish technical outlook with strong moving average signals and trades near pivot point resistance at $149. Fundamentally, the company demonstrates robust profitability with 82.9% gross margins and 19.9% net income margin, though recent quarters have seen earnings misses against expectations. Revenue growth continues with 2025 reaching $12.24 billion, supported by the company's asset-light model and global travel recovery.
The investment case balances strong fundamentals against valuation concerns, with a P/E of 36.5 suggesting premium pricing. Analyst consensus remains positive with a $161.80 price target, though recent earnings misses and CEO stock sales warrant monitoring. Key risks include travel demand sensitivity, competitive pressures, and execution of new initiatives like hotel expansion and AI development. The stock offers growth exposure to travel recovery but requires careful valuation assessment.
AMPH trades at $19.61, down 0.15% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 11.81 and net margin of 11%, but recent earnings misses and declining 2026 profit projections raise concerns. Recent news includes a Zacks Strong Sell rating and a securities law investigation, while management focuses on transitioning to proprietary drugs for growth.
The outlook remains cautious with analyst consensus at Hold (66.7%) and a $20.40 price target offering limited upside. Key risks include earnings volatility, competitive pressures, and legal scrutiny. The stock presents moderate value but requires careful monitoring of execution on growth initiatives and upcoming Q2 earnings.
Trailing returns across standard periods
Latest headlines on both assets
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →